granulocyte monocyte colony stimulating factor (Sanofi)
86
Structured Review
Sanofi
granulocyte monocyte colony stimulating factor
Granulocyte Monocyte Colony Stimulating Factor, supplied by Sanofi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/granulocyte+monocyte+colony+stimulating+factor/colony+factor+granulocyte+monocyte+stimulating/pm42249801-169-12-18
Average 86 stars, based on 1 article reviews
Granulocyte Monocyte Colony Stimulating Factor, supplied by Sanofi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/granulocyte+monocyte+colony+stimulating+factor/colony+factor+granulocyte+monocyte+stimulating/pm42249801-169-12-18
Average 86 stars, based on 1 article reviews
granulocyte monocyte colony stimulating factor - by Bioz Stars,
2026-11
86/100 stars
Images
Related Articles
Purification:Article Title: A universal monoallelic human leukocyte antigen class II immunopeptidomic platform for defining the immunogenicity potential of therapeutic proteins Article Snippet: On day 0, CD14+ cells were separated from the PBMCs by use of an AutoMACS instrument with anti-CD14 magnetic beads (Miltenyi Biotech). .. After viability determination with Trypan Blue (Thermo Fisher Scientific, Countess cell counter) purified CD14+ mononuclear cells were resuspended in complete RPMI Media (RPMI 1640 with 2 mM L-glutamine (Gibco), 5% Serum Replacement (Thermo Fisher Scientific), 5 mM HEPES (Gibco), 1% of 100X MEM nonessential amino acids (Gibco), 1% of 10,000 U/ml Penicillin/Streptomycin (HyClone), 1 mM sodium pyruvate (Gibco), 50 μM β-mercaptoethanol (Fisher Chemical), and 3.5% of DMEM high glucose (Gibco)) containing 40 ng/ml Article Title: A universal monoallelic human leukocyte antigen class II immunopeptidomic platform for defining the immunogenicity potential of therapeutic proteins. Article Snippet: On day 0, CD14+ cells were separated from the PBMCs by use of an AutoMACS instrument with anti-CD14 magnetic beads (Miltenyi Biotech). .. After viability determination with Trypan Blue (Thermo Fisher Scientific, Countess cell counter) purified CD14+ mononuclear cells were resuspended in complete RPMIMedia (RPMI 1640 with 2mM L-glutamine (Gibco), 5% Serum Replacement (Thermo Fisher Scientific), 5 mMHEPES (Gibco), 1% of 100XMEMnonessential amino acids (Gibco), 1% of 10,000 U/ml Penicillin/Streptomycin (HyClone), 1mM sodium pyruvate (Gibco), 50 μM β-mercaptoethanol (Fisher Chemical), and 3.5%ofDMEMhigh glucose (Gibco)) containing 40 ng/ml Cell Culture:Article Title: A universal monoallelic human leukocyte antigen class II immunopeptidomic platform for defining the immunogenicity potential of therapeutic proteins Article Snippet: On day 0, CD14+ cells were separated from the PBMCs by use of an AutoMACS instrument with anti-CD14 magnetic beads (Miltenyi Biotech). .. After viability determination with Trypan Blue (Thermo Fisher Scientific, Countess cell counter) purified CD14+ mononuclear cells were resuspended in complete RPMI Media (RPMI 1640 with 2 mM L-glutamine (Gibco), 5% Serum Replacement (Thermo Fisher Scientific), 5 mM HEPES (Gibco), 1% of 100X MEM nonessential amino acids (Gibco), 1% of 10,000 U/ml Penicillin/Streptomycin (HyClone), 1 mM sodium pyruvate (Gibco), 50 μM β-mercaptoethanol (Fisher Chemical), and 3.5% of DMEM high glucose (Gibco)) containing 40 ng/ml Article Title: A universal monoallelic human leukocyte antigen class II immunopeptidomic platform for defining the immunogenicity potential of therapeutic proteins. Article Snippet: On day 0, CD14+ cells were separated from the PBMCs by use of an AutoMACS instrument with anti-CD14 magnetic beads (Miltenyi Biotech). .. After viability determination with Trypan Blue (Thermo Fisher Scientific, Countess cell counter) purified CD14+ mononuclear cells were resuspended in complete RPMIMedia (RPMI 1640 with 2mM L-glutamine (Gibco), 5% Serum Replacement (Thermo Fisher Scientific), 5 mMHEPES (Gibco), 1% of 100XMEMnonessential amino acids (Gibco), 1% of 10,000 U/ml Penicillin/Streptomycin (HyClone), 1mM sodium pyruvate (Gibco), 50 μM β-mercaptoethanol (Fisher Chemical), and 3.5%ofDMEMhigh glucose (Gibco)) containing 40 ng/ml Recombinant:Article Title: A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence Article Snippet: .. Autologous dendritic cells were established by growing monocytes in the presence of Article Title: A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence. Article Snippet: .. Autologous dendritic cells were established by growing monocytes in the presence of Irradiation:Article Title: A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence Article Snippet: .. Autologous dendritic cells were established by growing monocytes in the presence of Article Title: A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence. Article Snippet: .. Autologous dendritic cells were established by growing monocytes in the presence of Expressing:Article Title: A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence Article Snippet: .. Autologous dendritic cells were established by growing monocytes in the presence of Article Title: A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence. Article Snippet: .. Autologous dendritic cells were established by growing monocytes in the presence of |